Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts – A case report  by Werthmann, Paul Georg et al.
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Background:  Cutaneous  squamous  cell  carcinoma  (CSCC)  is  a common  locally  invasive  skin cancer  which
rarely  metastasises.  First-line  treatment  is surgical  excision,  which  is  curative  in  most  cases.  Viscum  album
extract (VAE)  is  a widely  used  herbal  cancer  treatment  with  cytotoxic,  apoptogenic  and  immunologicalase report
effects,  but  has not  been  investigated  in CSCC.
Case presentation:  A  78-year-old  patient  with  histologically  diagnosed  CSCC  refused  surgical  excision  and
was  treated  with  peri-lesional  high-dose  VAE.  After  10  months  of  treatment  the  CSCC  had  disappeared
clinically.  The  patient  has been  recurrence-free  for  4 years.
Conclusion:  The  presented  case  shows  clinical  response  of  a  CSCC  to  high-dose  peri-lesional  VAE  injec-
tions.  Further  research  on  VAE  in  CSCC  is warranted.
 ntroduction
CSCC is the second most common skin cancer after basal cell
arcinoma, with a rising incidence. It is locally invasive, but per-
neural invasion and metastases in lymph nodes or other organs
re rare (Madan et al. 2010). Most of the lesions are asymptomatic,
hough pain, itching or recurrent bleeding may  occur. CSCC usu-
lly develops on sun exposed parts of the body (English et al.
998). Environmental risk factors for CSCC are accumulated UV
xposure, human papillomavirus, immunosuppression, photosen-
itising drugs, occupational factors, arsenic exposure and tobacco
moking. Personal risk factors are male gender and sun-sensitive
kin (Madan et al. 2010). Prognostic factors are state of disease,
orizontal and vertical size, localisation, histological features, and
mmunosuppression in the host.
Recommended treatment for the majority of CSCC cases is
urgical excision. Cryotherapy, electrosurgery and radiotherapy
re sometimes used in more superﬁcial and histologically well-
ifferentiated lesions. In high-risk lesions, Moh’s surgery shows the
est results regarding local recurrence and appearance of metas-
ases (Motley et al. 2009). Topical treatments with various agents
how diverse results in case series and small studies; side effects
re local skin reactions like erythema, swelling, desquamation
nd tenderness (Madan et al. 2010). Dysregulation of signalling
∗ Corresponding author. Tel.: +49 761 4534187; fax: +49 761 1560306.
E-mail address: paul.werthmann@ifaemm.de (P.G. Werthmann).
1 Deceased 31.07.2008.
944-7113     © 2012 Elsevier GmbH.  
ttp://dx.doi.org/10.1016/j.phymed.2012.11.001
Open access under CC BY-NC-ND license. © 2012 Elsevier GmbH. 
pathways in CSCC skin is under research and may  lead to new tar-
geted therapies in the future (Rodust et al. 2009). Overall cure rate
after therapy is higher than 90% for the ﬁrst 5 years. Primary lesions
recur in about 8% of cases, metastases appear in 5.5% (Rowe et al.
1992), and case fatality due to CSCC is about 1–2% (Marks 1995).
Patients with a primary lesion are at high risk (50%) of developing
further skin cancer lesions in the following 5 years (Karagas et al.
1992). Spontaneous remission in CSCC is rare (Chodorowski et al.
2007; O’Regan and Hirshberg 1993).
VAEs are aqueous extracts made from European mistletoe, a
hemi-parasitic plant that grows on different host trees (ash, birch,
apple, oak and others). Use of VAE in cancer treatment was  pio-
neered in anthroposophic medicine in the 1920s and today it is
widely used among cancer patients in central Europe (Molassiotis
et al. 2005). It is usually applied subcutaneously in low, slowly
increasing dosage, but higher dosage and intra- or peritumoural or
intravenous applications as well as instillations in visceral cavities
are used occasionally. Isolated compounds as well as whole extracts
of VAE are cytotoxic, induce apoptosis, activate lymphocytes, gra-
nulocytes, macrophages and NK-cells, induce different cytokines,
and show DNA stabilising properties (Büssing 2000; Kienle and
Kiene 2003a). Clinical studies show improvement of quality of life
(Kienle and Kiene 2010) and potential effect on survival (Kienle and
Kiene 2007). Tumour remissions were occasionally reported after
high doses and local application (Kienle and Kiene 2003b, 2007;
Open access under CC BY-NC-ND license.Kirsch 2007; Orange et al. 2010; Seifert et al. 2007). Side effects are
dose-dependent local skin reactions and ﬂu-like symptoms. Aller-
gic reactions have been reported. Altogether, VAE is considered to
be safe (Kienle and Kiene 2003a; Olaku and White 2010; Stein 2000;
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Fig. 1. Biopsy of the patient’s tumour (medium power view, 200×): cellular atypia
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Tn  all layers of the epidermis, epidermal tissue lying free in the connective tis-
ue  (subepidermal) with pleomorphism of nuclei, mitotic ﬁgures and giant nucleus
ormation.
tein and Berg 2000) even in high dose application (Kienle et al.
011).
ase presentation
An active 78-year-old patient with a past medical history of
eart disease (myocardial infarction, coronary bypass surgery)
ent to his general practitioner (GP) with an 11 mm ×7 mm
cabbed lesion (hyperkeratotic plaque with desquamation). He had
iscovered the lesion at the inner edge of his right eye a year before
ut felt no discomfort. In the dermatologic outpatient department
f the nearby university hospital (Fachklinik Hornheide, Münster),
 highly differentiated squamous cell carcinoma with a maximal
ertical tumour thickness of 0.8 mm was diagnosed through punch
iopsy (AJCC Classiﬁcation I without any high risk features (Farasat
t al. 2011)) (Fig. 1).
Surgical excision was proposed to the patient. The patient
efused surgery because of the highly sensitive localisation of
he tumour and his medical history of heart disease. His general
ractitioner suggested a peri-lesional VAE injection therapy. The
xperimental nature of this therapy and its uncertain outcome were
horoughly discussed with the patient, as well as other treatment
ptions such as surgery and radiation therapy.
Preparations of AbnobaVISCUM® were used. They are classi-
ed by the marketing authorisation in Germany according to the
h. Eur. monograph 01/2008:0765 EXTRACTS as “other extract”.
Other extracts” are determined by the production process with
eticulously deﬁned speciﬁcations resulting in pharmaceutically
omparable extracts. For “other extracts” the therapeutic active
rinciple is the whole extract. Thus, it is not allowed to declare
 certain content of a single constituent; for quality assurance
onstituents are measured regularly in a controlled and validated
nalysis process (ICH guideline Q2(R1)).
The treatment was started with VAE from the host tree ash
AbnobaVISCUM® Fraxini, vials of 0.02–2 mg;  2 mg  contain about
 g mistletoe lectin/ml, the ML-concentrations in lower doses
re respective) as peri-lesional ﬁne needle injections for 24 weeks
Table 1). In this time tumour size increased slowly. Because there
ere no signs of remission at this point, the VAE preparation
as changed to VAE from the host tree birch (AbnobaVISCUM®
etulae) in higher dosage (vials of 2–20 mg,  for details see
able 2; 20 mg  contain about 20 g mistletoe lectin/ml, and 59 gFig. 2. Photographs of the patient’s tumour. a: 3 weeks before VAE betulae; b: week
7  of VAE betulae; c: week 16 of VAE betulae; d: week 24 of VAE betulae.
viscotoxins/ml; the concentrations in lower doses are respective),
And after 4 weeks, a white scabbing developed over the lesion.
Another 7 weeks later, the scab had fallen off and the lesion had
decreased to <6 mm (largest diameter). Twenty weeks after the
change to high-dose VAE betulae, the original tumour site showed
only a small erythematous area without any signs of tumour growth
or scarring. (The course of the lesion is shown in photographs, taken
in intervals of 2 months: Fig. 2a–d.) The dermatologic department
(Fachklinik Hornheide, Münster) clinically conﬁrmed the complete
remission of the tumour. Biopsy for histological conﬁrmation of
remission was  refused by the patient. VAE treatment was contin-
ued with subcutaneous injections into the upper arm (3/week in
different dosages: 2 mg,  0.2 mg,  high dilution D10), carried out by
the patient’s wife at home; intermissions were later included (8
weeks of treatment followed by 4 weeks of intermission; then 4
weeks of treatment with 8 weeks of intermission, etc.).
Side effects of treatment were swelling of the skin at the injec-
tion site beginning about half an hour after application and lasting
about 48 h, as well as occasional itching of the face and scalp for
a few days. When VAE was used at higher dosages, periorbital
swelling led to visual restriction of the right eye. Dimetindene
(Fenistil®-drops, 1–1.5 mg  3×/d) was  prescribed once to control
itching.
At present, the 84-year-old patient is in a good state of health
and rides his bicycle 25–40 km per day. At a recent visit to a der-
matologist, no signs of recurrence were seen clinically. The patient
was  highly satisﬁed with this type of treatment and mentioned that
he would prefer this option in case of recurrence or other tumour
appearance.
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Table  1
VAE fraxini therapy.
Week of treatment VAE fraxini: perilesional injections per weeka Observations at the tumour siteb (initial tumour size:
11  mm × 7 mm)
0.02 mg  0.2 mga 2 mg
1 2
2 1c
3–4 2 No obvious change
5 2d Softening of the skin
6–8  2 Scabbing
9–11  1
12 1
13  1
14–21 1
22 1 1st photograph (Fig. 2 a)
23  0
24 1
a Vials for injection contained 1 ml;  of these, only 0.1–0.5 ml  were used for each injection depending on the inﬁltration dose tolerated by the patient.
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c No second injection because of swelling and reddening as a reaction to the prio
d First injection 0.02 mg,  second injection 0.02/0.2 mg  (1:1).
ntecedent and concomitant therapies
Besides coronary bypass surgery (see above), the patient had
ndergone hip replacement surgery on his right hip after a femoral
eck fracture. His coronary heart disease was treated with acetyl-
alicylic acid, metoprolol and Oleum strophanti. The myocardial
unction was not signiﬁcantly reduced.
No tumour-speciﬁc therapy was applied apart from VAE.
iscussion
The presented case shows a complete clinical remission of a low
isk CSCC under high-dose VAE treatment without recurrence in
he following 4 years (until publication). Histological diagnosis of
SCC (Fig. 1) was conﬁrmed by two independent dermatologists. As
pontaneous remission of CSCC is rare and no other speciﬁc ther-
py was used, we presume the remission to have occurred as a
esult of the high-dose VAE injections. Post-treatment biopsy of
able 2
AE betulae therapy, following VAE fraxini therapy (see Table 1).
Week of treatment VAE betulae: perilesional injections per 
2 mga 20 mg
1–2 1
3 1
4 1 
5  2b
6  1
7  1 
8–10  1
11  1 
12  1
13  0
14–15 1
16  1 
17  1
18  2
19  1
20  1 
21  0
22 1
23  1
24  0 
a Of the indicated vials of 1 ml  only 0.1–0.45 ml  were used for each injection depending
b Two injections were applied in week 5 because the course of disease had shown po
njections was  considered..
tion.
the tumour site could not be performed to conﬁrm the clinically
diagnosed remission of the tumour. Still, in view of the long-term
follow-up of the patient without any signs of recurrence, a complete
tumour remission is most likely.
Dose dependency may  be presumed because of lack of response
under lower dosages, and stronger local skin reactions (reddening
and swelling) and tumour remission under high dosage. The dif-
ference in effect may  also have been due to using mistletoe grown
on different host trees (Fraxinus versus Betula), but this seems less
likely as the active compounds in the preparations used are similar
(personal communication, Dr. Karin Schleisiek, Abnoba GmbH).
Tumour remissions with accompanying immunologic reactions
under high dose VAE, often intra- or peritumourally injected, have
been reported in other tumour entities as well, such as squamous
cell carcinoma of the oral cavity (Schefﬂer et al. 1996), primary cuta-
neous B-cell lymphoma (Orange et al. 2012), Merkel cell carcinoma
or breast cancer (Orange et al. 2010), and others (Kienle and Kiene
2003a, 2007). They have also been repeatedly observed in animal
week Observations at the tumour site
a
White scabbing
White scabbing 5 mm × 8 mm;
prescription of dimetindine
2nd photograph (Fig. 2b)
Scab had fallen off; tumour site < 6 mm
3rd photograph (Fig. 2c)
No palpable tumour, erythematous
area at previous site
4th photograph (Fig. 2d)
 on the inﬁltration dose tolerated by the patient.
sitive effects in the week before and therefore a regimen change to twice weekly
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xperiments (Büssing 2000; Kienle and Kiene 2003a).  Antitumoural
ffects of locally applied VAE may  be explained by their strong cyto-
oxic and apoptosis-inducing potency and by immune stimulating
ffects (e.g. activation of antigen-presenting cells, effector cells,
nduction of cytokines, and others) as seen in in vitro and in vivo
xperiments (Büssing 2000; Kienle and Kiene 2003a).  Still, further
esearch of the in vivo mode of action of VAE in tumours is needed,
specially histological and immunohistological analyses during and
fter local application of high dose VAE.
Local skin reactions like swelling of the surrounding skin as
ell as the erythema and itching are well known side effects of
AE (Kienle et al. 2011), and are also observed after application of
ther immune modulating therapies such as monoclonal antibod-
es or imiquimod (Alessi et al. 2009; Goodman et al. 1990; Madan
t al. 2010). The occurrence of such side effects during treatment
ith epidermal growth factor receptor inhibitor seems to predict a
etter clinical outcome (Wacker and Nagrani 2007).
This paper describes one single case and no other cases were
ound on VAE in CSCC. As the primary therapy of CSCC – surgical
xcision – is curative in most cases, with few risks, patients should
ot be advised to employ alternatives. Although CSCC has a rela-
ive good prognosis, it can still progress, inﬁltrate or metastasise if
ot treated properly and the risks of delaying or withholding sur-
ical excision have to be carefully balanced and critically discussed
Mistry et al. 2010). There can be situations as in the presented case
ith reasonable need for non-invasive treatment. Great interest
as been generated in the search of non-invasive therapy options
Madan et al. 2010), and research on VAE in CSCC is therefore warr-
nted.
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